$13.81
Insights on Liquidia Corp
Revenue is up for the last 2 quarters, 3.67M → 4.53M (in $), with an average increase of 18.8% per quarter
Netprofit is down for the last 2 quarters, -15.79M → -27.45M (in $), with an average decrease of 73.8% per quarter
1.52%
Downside
Day's Volatility :4.43%
Upside
2.95%
58.65%
Downside
52 Weeks Volatility :66.39%
Upside
18.72%
Period | Liquidia Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 3.9% | -0.7% | 0.0% |
6 Months | 136.52% | 6.6% | 0.0% |
1 Year | 98.57% | 3.7% | -1.5% |
3 Years | 194.89% | 14.0% | -21.8% |
Market Capitalization | 1.0B |
Book Value | $0.69 |
Earnings Per Share (EPS) | -1.21 |
Wall Street Target Price | 23.86 |
Profit Margin | 0.0% |
Operating Margin TTM | -583.45% |
Return On Assets TTM | -37.06% |
Return On Equity TTM | -114.01% |
Revenue TTM | 17.5M |
Revenue Per Share TTM | 0.27 |
Quarterly Revenue Growth YOY | -15.5% |
Gross Profit TTM | 13.1M |
EBITDA | -71.9M |
Diluted Eps TTM | -1.21 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.15 |
EPS Estimate Next Year | -0.34 |
EPS Estimate Current Quarter | -0.23 |
EPS Estimate Next Quarter | -0.25 |
What analysts predicted
Upside of 72.77%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 2.7M | ↓ 62.7% |
Net Income | -53.1M | ↑ 82.26% |
Net Profit Margin | -2.0K% | ↓ 1561.24% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 8.1M | ↑ 198.2% |
Net Income | -46.4M | ↓ 12.7% |
Net Profit Margin | -574.69% | ↑ 1388.23% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 739.6K | ↓ 90.84% |
Net Income | -57.5M | ↑ 23.93% |
Net Profit Margin | -7.8K% | ↓ 7198.3% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 12.9M | ↑ 1637.81% |
Net Income | -29.8M | ↓ 48.2% |
Net Profit Margin | -231.7% | ↑ 7541.29% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 15.9M | ↑ 23.98% |
Net Income | -38.4M | ↑ 28.82% |
Net Profit Margin | -240.76% | ↓ 9.06% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 17.5M | ↑ 9.75% |
Net Income | -78.5M | ↑ 104.62% |
Net Profit Margin | -448.89% | ↓ 208.13% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.2M | ↓ 19.22% |
Net Income | -9.4M | ↓ 1.0% |
Net Profit Margin | -295.51% | ↓ 54.39% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 5.4M | ↑ 69.35% |
Net Income | -6.0M | ↓ 36.2% |
Net Profit Margin | -111.32% | ↑ 184.19% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.5M | ↓ 16.18% |
Net Income | -13.1M | ↑ 120.11% |
Net Profit Margin | -292.32% | ↓ 181.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.8M | ↑ 6.52% |
Net Income | -23.5M | ↑ 79.05% |
Net Profit Margin | -491.37% | ↓ 199.05% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.7M | ↓ 23.15% |
Net Income | -15.8M | ↓ 32.86% |
Net Profit Margin | -429.31% | ↑ 62.06% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.5M | ↑ 23.19% |
Net Income | -27.5M | ↑ 73.84% |
Net Profit Margin | -605.83% | ↓ 176.52% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 49.4M | ↑ 232.93% |
Total Liabilities | 30.7M | ↓ 36.68% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 68.8M | ↑ 39.3% |
Total Liabilities | 33.9M | ↑ 10.3% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 99.5M | ↑ 44.58% |
Total Liabilities | 28.4M | ↓ 16.08% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 93.7M | ↓ 5.83% |
Total Liabilities | 28.5M | ↑ 0.06% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 129.2M | ↑ 37.84% |
Total Liabilities | 38.8M | ↑ 36.23% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 120.4M | ↓ 6.79% |
Total Liabilities | 73.1M | ↑ 88.62% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 132.6M | ↓ 4.68% |
Total Liabilities | 37.5M | ↑ 1.51% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 129.2M | ↓ 2.54% |
Total Liabilities | 38.8M | ↑ 3.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 128.9M | ↓ 0.21% |
Total Liabilities | 47.3M | ↑ 21.93% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 121.6M | ↓ 5.68% |
Total Liabilities | 60.9M | ↑ 28.89% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 111.6M | ↓ 8.19% |
Total Liabilities | 63.6M | ↑ 4.42% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 120.4M | ↑ 7.87% |
Total Liabilities | 73.1M | ↑ 14.93% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -31.8M | ↑ 31.04% |
Investing Cash Flow | -870.9K | ↓ 65.77% |
Financing Cash Flow | 68.8M | ↑ 138.83% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -48.3M | ↑ 51.69% |
Investing Cash Flow | -1.9M | ↑ 112.42% |
Financing Cash Flow | 66.4M | ↓ 3.52% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -54.1M | ↑ 12.14% |
Investing Cash Flow | 247.9K | ↓ 113.4% |
Financing Cash Flow | 63.4M | ↓ 4.48% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -34.0M | ↓ 37.14% |
Investing Cash Flow | -107.2K | ↓ 143.25% |
Financing Cash Flow | 26.3M | ↓ 58.5% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.6M | ↓ 16.01% |
Investing Cash Flow | -587.0K | ↑ 447.47% |
Financing Cash Flow | 65.0M | ↑ 146.82% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.8M | ↓ 31.5% |
Investing Cash Flow | -94.0K | ↑ 4600.0% |
Financing Cash Flow | 348.0K | ↓ 99.36% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.6M | ↓ 20.28% |
Investing Cash Flow | -491.0K | ↑ 422.34% |
Financing Cash Flow | 57.0K | ↓ 83.62% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.5M | ↑ 83.73% |
Investing Cash Flow | -243.0K | ↓ 50.51% |
Financing Cash Flow | 10.0M | ↑ 17356.14% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.6M | ↓ 34.21% |
Investing Cash Flow | -243.0K | ↑ 0.0% |
Financing Cash Flow | -409.0K | ↓ 104.11% |
Sell
Neutral
Buy
Liquidia Corp is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Liquidia Corp | -10.93% | 136.52% | 98.57% | 194.89% | 194.89% |
Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Liquidia Corp | NA | NA | NA | -1.15 | -1.14 | -0.37 | NA | 0.69 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Liquidia Corp | Buy | $1.0B | 194.89% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Caligan Partners LP
BlackRock Inc
Vanguard Group Inc
Kynam Capital Management, LP
Findell Capital Management LLC
Geode Capital Management, LLC
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Organization | Liquidia Corp |
Employees | 145 |
CEO | Dr. Roger A. Jeffs Ph.D. |
Industry | Health Technology |